These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 6497565)

  • 61. Twin concordance for operationally defined schizophrenia. Confirmation of familiality and heritability.
    McGuffin P; Farmer AE; Gottesman II; Murray RM; Reveley AM
    Arch Gen Psychiatry; 1984 Jun; 41(6):541-5. PubMed ID: 6539584
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Apomorphine stimulation of vasopressin- and oxytocin-neurophysins. Evidence for increased oxytocinergic and decreased vasopressinergic function in schizophrenics.
    Legros JJ; Gazzotti C; Carvelli T; Franchimont P; Timsit-Berthier M; von Frenckell R; Ansseau M
    Psychoneuroendocrinology; 1992 Nov; 17(6):611-7. PubMed ID: 1287681
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A neuroendocrine study of supersensitivity in tardive dyskinesia.
    Tamminga CA; Smith RC; Pandey G; Frohman LA; Davis JM
    Arch Gen Psychiatry; 1977 Oct; 34(10):1199-203. PubMed ID: 911219
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Some comments on Schneider's first rank symptoms].
    Suwa N
    Seishin Shinkeigaku Zasshi; 1983; 85(2):112-6. PubMed ID: 6867192
    [No Abstract]   [Full Text] [Related]  

  • 65. [Neuroendocrinology and schizophrenia research].
    Müller-Spahn F
    Monogr Gesamtgeb Psychiatr Psychiatry Ser; 1991; 64():1-96. PubMed ID: 1682802
    [No Abstract]   [Full Text] [Related]  

  • 66. Apomorphine and the dopamine hypothesis of schizophrenia: a dilemma?
    Dépatie L; Lal S
    J Psychiatry Neurosci; 2001 May; 26(3):203-20. PubMed ID: 11394190
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Dopamine function in obsessive-compulsive disorder: growth hormone response to apomorphine stimulation.
    Brambilla F; Bellodi L; Perna G; Arancio C; Bertani A
    Biol Psychiatry; 1997 Nov; 42(10):889-97. PubMed ID: 9359974
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Biological studies of DSM-III psychotic disorders. I. Platelet measures and apomorphine-induced growth hormone response.
    Meltzer HY; Perline R; Lewine R
    J Nerv Ment Dis; 1982 Dec; 170(12):758-65. PubMed ID: 6754871
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Cultural relativety of first rank symptoms in schizophrenia.
    Pela OA
    Int J Soc Psychiatry; 1982; 28(2):91-5. PubMed ID: 7107146
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A cross-cultural study of the frequencies of Schneider's first rank symptoms of schizophrenia.
    Ndetei DM; Vadher A
    Acta Psychiatr Scand; 1984 Dec; 70(6):540-4. PubMed ID: 6524419
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effect of the placebo control condition in neuroendocrine challenge studies.
    Thompson PA; Maes M; Meltzer HY
    Psychiatry Res; 1994 Jun; 52(3):317-26. PubMed ID: 7991724
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Prediction of outcome in first-episode schizophrenia.
    Lieberman JA
    J Clin Psychiatry; 1993 Mar; 54 Suppl():13-7. PubMed ID: 8097192
    [TBL] [Abstract][Full Text] [Related]  

  • 73. First rank symptoms of schizophrenia: questions concerning clinical boundaries.
    Koehler K
    Br J Psychiatry; 1979 Mar; 134():236-48. PubMed ID: 509005
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Study of the diagnostic specificity by Schneider's first rank symptoms].
    Wu Y
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1990 Apr; 23(2):79-80, 126. PubMed ID: 2390876
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Multidiagnostic evaluation of prolactin response to haloperidol challenge in schizophrenia: maximal blunting in Kraepelinian patients.
    Keks NA; McKenzie DP; Low LH; McGorry PD; Hill C; Kulkarni J; Singh BS; Copolov DL
    Biol Psychiatry; 1992 Sep; 32(5):426-37. PubMed ID: 1486148
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Methylphenidate response, psychopathology and tardive dyskinesia as predictors of relapse in schizophrenia.
    Lieberman JA; Alvir J; Geisler S; Ramos-Lorenzi J; Woerner M; Novacenko H; Cooper T; Kane JM
    Neuropsychopharmacology; 1994 Oct; 11(2):107-18. PubMed ID: 7840862
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Circadian and sleep-related endocrine rhythms in schizophrenia.
    Van Cauter E; Linkowski P; Kerkhofs M; Hubain P; L'Hermite-Balériaux M; Leclercq R; Brasseur M; Copinschi G; Mendlewicz J
    Arch Gen Psychiatry; 1991 Apr; 48(4):348-56. PubMed ID: 1848971
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The usefulness of first-rank symptoms in the diagnosis of schizophrenia in a Saudi Arabian population.
    Zarrouk ET
    Br J Psychiatry; 1978 Jun; 132():571-3. PubMed ID: 656725
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Serum prolactin, psychopathology, and ventricular size in chronic schizophrenia.
    Luchins DJ; Robertson AG; Meltzer HY
    Psychiatry Res; 1984 Jun; 12(2):149-53. PubMed ID: 6147869
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Schizophrenia: the nature of the psychological disturbance and its possible neurochemcial basis.
    Crow TJ
    Ciba Found Symp; 1979; (69):335-43. PubMed ID: 44859
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.